The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting was held June 1 – 5 at McCormick Place in Chicago, Illinois.
Photo by © ASCO/Rodney White 2017

Gene signature might identify patients at risk of CAR T-associated neurotoxicity

Print Friendly, PDF & Email


Attendees at ASCO 2018 Annual Meeting
Photo by © ASCO/Zach Boyden-Holmes 2018
A specific gene signature might be able to identify patients at risk of CD19 CAR T-cell associated neurotoxicity, according to results of an exploratory analysis presented at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO). The analysis, based on... [Read Article]
Print Friendly, PDF & Email

Peripheral blood MRD correlates with treatment benefit in CLL

Print Friendly, PDF & Email


Poster session at ASCO 2018
Photo by © ASCO/Scott Morgan 2018
Minimal residual disease (MRD) kinetics confirms the high, durable MRD-negativity with venetoclax plus rituximab in relapsed/refractory chronic lymphocytic leukemia (CLL), according to a further examination of the phase 3 MURANO study. The new results show higher concordance in MRD-negativity between bone marrow and peripheral... [Read Article]
Print Friendly, PDF & Email

Efficacy of KTE-C19 CAR T cells not compromised by prior blinatumomab

Print Friendly, PDF & Email


McCormick Place during 2018 ASCO Annual Meeting
Photo by © ASCO/Rodney White 2018
Prior exposure to blinatumomab does not appear to affect the successful manufacture of KTE-C19 or its efficacy in patients with relapsed/refractory acute lymphoblastic leukemia (ALL). The clinical benefit of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, was preserved regardless of... [Read Article]
Print Friendly, PDF & Email

Interim PET scans identify HL patients with better outcomes

Print Friendly, PDF & Email


Micrograph showing Hodgkin lymphoma
Interim PET scans can identify a subset of Hodgkin lymphoma (HL) patients with a better outcome suitable for de-escalation treatment after upfront BEACOPP without impairing disease control, according to final results of the AHL2011-LYSA study. BEACOPP, compared to ABVD, improves progression-free survival (PFS) but not overall survival (OS) and is associated... [Read Article]
Print Friendly, PDF & Email

Ivosidenib active in R/R IDH1-mutated AML patients

Print Friendly, PDF & Email


Poster session at ASCO 2018
Photo by © ASCO/Scott Morgan 2018
The investigational drug ivosidenib, an inhibitor of the mutant IDH1 enzyme, achieved complete remission (CR) rates of 32% and an overall response rate of 42% in relapsed/refractory (R/R) patients with acute myeloid leukemia (AML) and IDH1 mutation, according to investigators. In addition, overall survival... [Read Article]
Print Friendly, PDF & Email

Ibrutinib and venetoclax combo promising in front-line CLL

Print Friendly, PDF & Email


Attendees at ASCO 2018 Annual Meeting
Photo by © ASCO/Zach Boyden-Holmes 2018
Ibrutinib combined with venetoclax is showing promising clinical activity in the front-line treatment of patients with chronic lymphocytic leukemia (CLL), according to investigators for the CAPTIVATE study. In the first 30 patients, 77% of treatment-naïve patients had undetected minimal residual disease (MRD) in... [Read Article]
Print Friendly, PDF & Email

Chemo-free combo provides potential first-line option for FL

Print Friendly, PDF & Email


Attendee at ASCO 2018
Photo by © ASCO/Scott Morgan 2018
A chemotherapy-free combination of lenalidomide plus rituximab shows similar efficacy and a different safety profile to chemotherapy plus rituximab (R-chemo) followed by rituximab maintenance in patients with previously untreated follicular lymphoma (FL). According to investigators, the multicenter, international phase 3 RELEVANCE trial is the first... [Read Article]
Print Friendly, PDF & Email

bb2121 demonstrates durable responses, manageable toxicity in MM

Print Friendly, PDF & Email


Noopur S. Raje, MD
Photo by Andrew D. Bowser
bb2121, the anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, induced deep and durable ongoing responses in heavily pretreated multiple myeloma (MM) patients, updated results of a phase 1 study show. At active doses (≥150 x 108 CAR+ T cells), the B-cell maturation antigen (BCMA)-targeted therapy had... [Read Article]
Print Friendly, PDF & Email

Pomalidomide triplet significantly extends PFS in R/R MM

Print Friendly, PDF & Email


ASCO 2018 attendees at a poster session
Photo by © ASCO/Scott Morgan 2018
The addition of pomalidomide to bortezomib and low‐dose dexamethasone (PVd) significantly improves progression-free survival (PFS) in lenalidomide-exposed patients with relapsed or refractory (R/R) multiple myeloma (MM). Up until now, pomalidomide and dexamethasone (Pd) had been the only therapy investigated exclusively after lenalidomide... [Read Article]
Print Friendly, PDF & Email

Polatuzumab plus BR improves efficacy in DLBCL

Print Friendly, PDF & Email


Attendees at ASCO 2018 Annual Meeting
Photo by © ASCO/Zach Boyden-Holmes 2018
Polatuzumab vedotin, when added to bendamustine (B) and rituximab (R), significantly improved response and survival rates in a cohort of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to randomized phase 2 study results. By contrast, there were no such improvements in... [Read Article]
Print Friendly, PDF & Email